Showing 4781-4790 of 8859 results for "".
- FDA Approves of Sol Gel's Twyneo for Acnehttps://practicaldermatology.com/news/fda-approves-of-sol-gels-twyneo-for-acne/2460874/The FDA has approved Sol Ge's first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel’s patented technology to entrap tretinoin, a retinoid, a
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- FDA Delays Review of Pfizer’s Abrocitinib and Xeljanz Filingshttps://practicaldermatology.com/news/fda-delays-review-of-pfizers-abrocitinib-and-xeljanz-filings/2460870/The U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis and the supplemental New Drug Application for Xeljanz/
- Allergan Aesthetics Continues Partnership with Girls Inc.https://practicaldermatology.com/news/allergan-aesthetics-continues-partnership-with-girls-inc/2460869/Allergan Aesthetics is starting its third consecutive year of partnership with Girls Inc. and debuting Empowering Confidence Workshops, a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in science, technology, eng
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less
- Rhode Island Takes Steps to Increase Sunscreen Access for Childrenhttps://practicaldermatology.com/news/rhode-island-takes-steps-to-increase-sunscreen-access-for-children/2460866/Rhode Island students will now be able to possess and utilize sunscreen at school and school-related activities, thanks to advocacy from the American Society for Dermatologic Surgery Association (ASDSA) and the Rhode Island Dermatology Society. Governor Daniel McKee signed into la
- Sunscreen Recall: J & J Pulls Five Sunscreens Due to Benzene Contaminationhttps://practicaldermatology.com/news/sunscreen-recall-j-j-pulls-five-sunscreens-due-to-benzene-contamination/2460865/Johnson & Johnson is recalling five Neutrogena and Aveeno aerosol sunscreens after finding low levels of benzene in some samples. The recalled sunscreen products include: AVEENO PROTECT + REFRESH aerosol sunscreen NEUTROGENA Beach Def
- Amgen, International Federation of Psoriasis Associations Launch UPLIFT Innovation Challengehttps://practicaldermatology.com/news/amgen-international-federation-of-psoriasis-associations-launch-uplift-innovation-challenge/2460862/Amgen and the International Federation of Psoriasis Associations are launching the
- Arcutis Enrolls First Patient in Phase 3 Trial of Roflumilast for SDhttps://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-3-trial-of-roflumilast-for-sd/2460860/The first patient has been enrolled in the pivotal Phase 3 clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for seborrheic dermatitis. Arcutis Biotherapeutics, Inc. is develo
- FDA Approves New Cheek Filler from Galdermahttps://practicaldermatology.com/news/fda-approves-new-cheek-filler-from-galderma/2460856/The U.S. Food and Drug Administration (FDA) approved Galderma’s Restylane Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Restylane Contour, a new hyaluronic acid (HA) dermal filler, is Galde